<br />
ONCOLOGY<br />
EMJ Oncol. 2018 Suppl 2 • europeanmedical-journal.com<br />
INSIDE<br />
Realising the Full Potential<br />
of Biosimilars: Interviews with<br />
Three Key Opinion Leaders<br />
Realising the Full Potential of Biosimilars:<br />
Interviews with Three Key Opinion Leaders<br />
Interviewees: Huub Schellekens,1 Paul Cornes,2 Martin Dreyling3<br />
1. Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences<br />
(UIPS), Utrecht University, Utrecht, Netherlands<br />
2. Comparative Outcomes Group, Bristol, UK<br />
3. Department of Medicine III, University Hospital, Ludwig Maximilian University<br />
(LMU), Munich, Germany<br />
Disclosure: Prof Schellekens has declared no conflicts of interest. Dr Cornes has received<br />
advisory board fees from Astro Pharma, Mylan, and Pfizer/Hospira; and has received<br />
<a title="EMJ Oncol. 2018 Suppl 2 page 1" href="http://viewer.zmags.com/publication/502431e6?page=1"> ONCOLOGY EMJ Oncol. 2018 Suppl 2 • europeanmedica</a>
<a title="EMJ Oncol. 2018 Suppl 2 page 2" href="http://viewer.zmags.com/publication/502431e6?page=2"> Realising the Full Potential of Biosimilars: Int</a>
<a title="EMJ Oncol. 2018 Suppl 2 page 3" href="http://viewer.zmags.com/publication/502431e6?page=3"> commented. “I was co-steer of the European School</a>
<a title="EMJ Oncol. 2018 Suppl 2 page 4" href="http://viewer.zmags.com/publication/502431e6?page=4"> acceptance of biosimilars among oncologists, </a>
<a title="EMJ Oncol. 2018 Suppl 2 page 5" href="http://viewer.zmags.com/publication/502431e6?page=5"> in inflammatory bowel disease patients at Uni</a>
<a title="EMJ Oncol. 2018 Suppl 2 page 6" href="http://viewer.zmags.com/publication/502431e6?page=6"> "We know that if you develop a biosimilar or </a>
<a title="EMJ Oncol. 2018 Suppl 2 page 7" href="http://viewer.zmags.com/publication/502431e6?page=7"> rates. The same has happened for some prior suppo</a>
<a title="EMJ Oncol. 2018 Suppl 2 page 8" href="http://viewer.zmags.com/publication/502431e6?page=8"> he has a particular interest in. “I am in</a>
<a title="EMJ Oncol. 2018 Suppl 2 page 9" href="http://viewer.zmags.com/publication/502431e6?page=9"> Prof Martin Dreyling Ludwig Maximilian Universit</a>